Table 1. Global overview of active clinical trials in Maghreb countries.

Clinical trial identifier	Trial design	Condition	Intervention	Sponsor Institution	Status	Country
Impassion 132 NCT03371017	Interventional phase III, double blind, placebo control, randomised	Early recurrent, advanced triple negative breast cancer	Atezolizumab or placebo plus chemotherapy	Pharmaceutical company	Recruiting	Algeria Morocco
SAFIA NCT03447132	Interventional phase III, double blind, placebo control, randomised	Operable luminal breast cancer	Fulvestrant vs fulvestrant plus palbociclib	Pharmaceutical company + funding from research organisation	Active not Recruiting	Algeria Morocco Tunisia
SKYSCRAPER-07- NCT04543617	Interventional phase III, double blind, placebo control, randomised	Unresectable oesophageal squamous cell carcinoma	Tiragolumab or placebo plus atezolizumab	Pharmaceutical company	Pending approval from health authorities	Morocco
ICRG0201 NCT05190094	Interventional, open label, phase II, single-arm trial	Hormonal-positive HER2-negative advanced breast cancer,	Combination of palbociclib and aromatase inhibitor. Prediction of treatment efficacy using liquid biopsies.	Research organisation	Recruiting	Algeria